(Q38909657)

7 September 2017

The high price of anticancer drugs: origins, implications, barriers, solutions (English)

1 reference

7 September 2017

1

1 reference

7 September 2017

3

Sham Mailankody

1 reference

7 September 2017

Kevin De Jesús

2

1 reference

PubMed ID

28290490

7 September 2017

language of work or name

English

0 references

publication date

14 March 2017

1 reference

Nature Reviews Clinical Oncology

7 September 2017

1 reference

7 September 2017

14

1 reference

7 September 2017

6

1 reference

7 September 2017

381-390

1 reference

Five Years of Cancer Drug Approvals: Innovation, Efficacy, and Costs.

7 September 2017

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.31

Projections of the cost of cancer care in the United States: 2010-2020.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.31

Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.31

Pembrolizumab for the treatment of non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.31

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.31

Pembrolizumab versus Ipilimumab in Advanced Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.31

Perspectives on Cost and Value in Cancer Care.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.31

The Rising Price of Cancer Drugs-A New Old Problem?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.31

Food price and diet and health outcomes: 20 years of the CARDIA Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.31

The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.31

In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.31

Unintended consequences of expensive cancer therapeutics—the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: the John Conley Lecture

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.31

An Appraisal of Clinically Meaningful Outcomes Guidelines for Oncology Clinical Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.31

Clinical Trial Participants With Metastatic Renal Cell Carcinoma Differ From Patients Treated in Real-World Practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.31

Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.31

Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.31

A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.31

Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.31

Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.31

First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: a United States-based cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.31

The Ethical and Practical Challenges of Value-Based Cancer Care at the Patient's Bedside.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.31

Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.31

Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.31

Value of innovation in hematologic malignancies: a systematic review of published cost-effectiveness analyses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.31

Are high drug prices for hematologic malignancies justified? A critical analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.31

How should we assess the value of innovative drugs in oncology? Lessons from cost-effectiveness analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.31

Bias in published cost effectiveness studies: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.31

The $2.6 billion pill--methodologic and policy considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.31

Innovation in the pharmaceutical industry: New estimates of R&D costs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.31

The Role of Public-Sector Research in the Discovery of Drugs and Vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.31

What are the respective roles of the public and private sectors in pharmaceutical innovation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.31

The importance of new companies for drug discovery: origins of a decade of new drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.31

Systematic review: reliability of compendia methods for off-label oncology indications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.31

Washington State cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.31

Financial Insolvency as a Risk Factor for Early Mortality Among Patients With Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.31

Factors Associated With Tyrosine Kinase Inhibitor Initiation and Adherence Among Medicare Beneficiaries With Chronic Myeloid Leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.31

Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.31

Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.31

Medicare D Subsidies and Racial Disparities in Persistence and Adherence With Hormonal Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.31

ESMO European Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in Europe.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.31

The UK Cancer Drugs Fund Experiment and the US Cancer Drug Cost Problem: Bearing the Cost of Cancer Drugs Until It Is Unbearable.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.31

Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.31

How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.31

Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.31

Ethics of Clinical Trials in Low-Resource Settings: Lessons From Recent Trials in Cancer Medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.31

Strategies that delay or prevent the timely availability of affordable generic drugs in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.31

Target prices for mass production of tyrosine kinase inhibitors for global cancer treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.31

Generic Drug Approvals Since the 1984 Hatch-Waxman Act.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.31

The High Cost of Prescription Drugs in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.31

Implications of Proposed Medicare Reforms to Counteract High Cancer Drug Prices

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.31

Cancer Drugs Fund requires further reform

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.31

'Government Patent Use': A Legal Approach To Reducing Drug Spending

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.31

More Is Not Always Better: Intuitions About Effective Public Policy Can Lead to Unintended Consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.31

Comparative Effectiveness Questions in Oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.31

Limits on Medicare's ability to control rising spending on cancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.31

Drug Pricing Trends for Orally Administered Anticancer Medications Reimbursed by Commercial Health Plans, 2000-2014

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.31

Addressing the quality of the ESMO-MCBS

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.31

Overall Survival in Cancer Drug Trials as a New Surrogate End Point for Overall Survival in the Real World

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.31

Pricing in the Market for Anticancer Drugs.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.31

State Initiatives to Control Medication Costs--Can Transparency Legislation Help?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.31

New 50 million pound cancer fund already intellectually bankrupt

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.31

Using a drug-safety tool to prevent competition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.31

Use the Bayh-Dole Act to lower drug prices for government healthcare programs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2017.31

Out-of-pocket costs and oral cancer medication discontinuation in the elderly

31 March 2020

1 reference

12 December 2020

Variations in time of market exclusivity among top-selling prescription drugs in the United States

1 reference

12 December 2020

Do Contemporary Randomized Controlled Trials Meet ESMO Thresholds for Meaningful Clinical Benefit?

1 reference

12 December 2020

US drug spending hits $425 billion

1 reference

12 December 2020

10.1038/NRCLINONC.2017.31

Identifiers

DOI

1 reference

7 September 2017

1 reference

PubMed ID

28290490